Skip to content
Screener

Ocular Therapeutix OCUL Business Segments — Allocated Share Based Compensation Expense

Similar metrics at other companies

Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Allocated Share Based Compensation Expense
$8.72M-3.8%
Vuzix logo
VUZISingle Reportable — Allocated Share Based Compensation Expense
$4.11M-24.0%
Research Solutions logo
RSSSSingle Reportable — Allocated Share Based Compensation Expense
$248.61K-58.2%
Protagonist Therapeutics logo
PTGXSingle Reportable — Allocated Share Based Compensation Expense
$14.04M+28.6%
uniQure logo
QURESingle Reportable — Allocated Share Based Compensation Expense
$5.02M-1.3%
Farmland Partners logo
FPISingle Reportable — Allocated Share Based Compensation Expense
-$468K+9.8%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$1.92B-11.7%
Enterprise value$1.33B-28.4%
P/S36.9×-1.5×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055256
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Research and development$5,457$3,018
Selling and marketing2,2371,177
General and administrative7,8886,261
$15,582$10,456

Item 1. Financial Statements (unaudited)

FAQ

What is Ocular Therapeutix's business segments — allocated share based compensation expense?
Ocular Therapeutix (OCUL) reported business segments — allocated share based compensation expense of $15.58M in Q1 2026.
How has Ocular Therapeutix's business segments — allocated share based compensation expense changed year-over-year?
Ocular Therapeutix's business segments — allocated share based compensation expense increased by 49.0% year-over-year, from $10.46M to $15.58M.
What is the long-term trend for Ocular Therapeutix's business segments — allocated share based compensation expense?
Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — allocated share based compensation expense has grown at a 36.5% compound annual growth rate (CAGR), from -$16.96M to $43.18M.
What does business segments — allocated share based compensation expense mean?
This represents the non-cash expense recognized for equity-based awards granted to employees and contractors within the business segment. It is a critical component for understanding the total cost of talent and the dilutive impact of compensation strategies.

Ask your AI about Ocular Therapeutix's business segments — allocated share based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude